Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 44.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,699 shares of the biopharmaceutical company's stock after buying an additional 10,379 shares during the period. ProShare Advisors LLC's holdings in Catalyst Pharmaceuticals were worth $703,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Summit Investment Advisors Inc. increased its stake in Catalyst Pharmaceuticals by 5.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 580 shares during the last quarter. Bank of Montreal Can increased its position in Catalyst Pharmaceuticals by 6.2% during the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 875 shares during the period. Rhumbline Advisers lifted its holdings in Catalyst Pharmaceuticals by 0.3% in the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after acquiring an additional 952 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Catalyst Pharmaceuticals by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock worth $740,000 after purchasing an additional 1,000 shares in the last quarter. Finally, PDT Partners LLC grew its stake in shares of Catalyst Pharmaceuticals by 5.2% during the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock worth $431,000 after purchasing an additional 1,030 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on CPRX shares. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $32.29.

Catalyst Pharmaceuticals Trading Up 0.7%

CPRX traded up $0.17 during trading on Friday, hitting $24.75. 121,913 shares of the company's stock were exchanged, compared to its average volume of 1,100,853. The stock has a 50 day moving average price of $23.59 and a 200 day moving average price of $22.59. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.75 and a 1 year high of $26.16. The firm has a market cap of $3.02 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 351,879 shares of company stock valued at $8,214,815 in the last ninety days. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.